Trends in antimicrobial resistance of extended-spectrum beta-lactamase-producing Escherichia coli in urinary tract infections in ICU and non-ICU settings at Ngoerah Hospital, 2020-2022
Main Article Content
Keywords
Urinary Tract Infection, Escherichia coli, ESBL, Antibiotic Resistance, ICU, Non-ICU
Abstract
Background: Urinary Tract Infection (UTI) is one of the most common nosocomial infections, with Escherichia coli (E. coli) as the primary pathogen. The misuse and overuse of antibiotics has led to the emergence of antibiotic resistance, particularly in Extended-Spectrum Beta-Lactamase (ESBL)-producing E. coli. This resistance presents a significant challenge in managing UTIs, especially among ICU and non-ICU ward patients. This study aims to analyze trends in antibiotic resistance of ESBL-producing E. coli in UTI patients in ICU and non-ICU settings at Ngoerah Hospital during 2020–2022.
Methods: A descriptive study with a cross-sectional approach was conducted. The inclusion criteria of this study were samples with identification results of E. coli bacteria with VITEK 2 Compact (bioMérieux, France), which showed E. coli with a probability greater than or equal to 90% and accompanied by sensitivity of E. coli bacteria to antibiotics.
Result: Among 789 samples meeting inclusion criteria, 90% (714) were from non-ICU wards, while 10% (75) were from ICU wards. ESBL-producing E. coli accounted for 53% (416), while non-ESBL strains constituted 47% (373). The prevalence of ESBL-producing E. coli in non-ICU wards increased from 43% (96 isolates) in 2020 to 47% (129 isolates) in 2021 and 51% (149 isolates) in 2022. In ICU wards, prevalence rose from 3% (6 isolates) in 2020 to 4% (12 isolates) in 2021 and 8% (24 isolates) in 2022. Tigecycline, meropenem, and ertapenem demonstrated high sensitivity (≥96%), while beta-lactam antibiotics like ampicillin, cefixime, and cefazolin showed 100% resistance.
Conclusion: The increasing resistance of ESBL-producing E. coli, particularly in non-ICU settings, highlights the need for strict antibiotic policies and monitoring to prevent further resistance.
References
2. Irawan E, Mulyana H. Faktor-Faktor Penyebab Infeksi Saluran Kemih (ISK) [Internet]. Prosiding Seminar Nasional dan Penelitian Kesehatan 2018;1:2013–6. [Tersedia pada: https://osf.io/yt8nz] [Diakses pada: 11 Januari 2025]
3. Skrzat-Klapaczyńska A, Matłosz B, Bednarska A, Paciorek M, Firląg-Burkacka E, Horban A, et al. Factors associated with urinary tract infections among HIV-1 infected patients. PLoS One. 2018;13(1):e0190564. Published 2018 Jan 11. doi:10.1371/journal.pone.0190564.
4. Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10(12):6235-6254. doi:10.3390/ijerph10126235.
5. Arivo D, Dwiningtyas AW. Pola kepekaan Escherichia coli penyebab infeksi saluran kemih terhadap antibiotik. J Farm Malahayati. 2019;2(1):12–23. doi:10.33024/jfm.v2i1.1540.
6. Rahayu WP, Nurjanah S, Komalasari E. Escherichia coli: patogenitas, analisis dan kajian risiko. Bogor: IPB Press; 2018:1–151.
7. Lindayanti, Muzahar, Lubis AR. Pola resistensi antimikroba pada infeksi saluran kemih yang disebabkan oleh bakteri penghasil ESBL dan non‑ESBL. Majalah Kedokteran Nusantara. 2014;47(2):77–81
8. Normaliska R, Sudarwanto MB, Latif H. Pola Resistensi Antibiotik pada Escherichia coli Penghasil ESBL dari Sampel Lingkungan di RPH‑R Kota Bogor. Acta Vet Indones. 2019;7(2):42–48.
9. Wijaya C, Eriata AH, Rustawan INT, Candra IKB, Budayanti NNS. Prevalence of uropathogen producing extended spectrum beta lactamase (ESBL) at urinary tract infection in chronic kidney disease patients. J Clin Microbiol Infect Dis. 2023;3(1):12–15. doi:10.51559/jcmid.v3i1.29
10. Abalkhail A, AlYami AS, Alrashedi SF, Almushayqih KM, Alslamah T, Alsalamah YA, et al. The Prevalence of Multidrug-Resistant Escherichia coliProducing ESBL among Male and Female Patients with Urinary Tract Infections in Riyadh Region, Saudi Arabia. Healthcare (Basel). 2022;10(9):1778.. doi:10.3390/healthcare10091778.
11. Rowe TA, Juthani‑Mehta M. Urinary tract infection in older adults. Aging Health. 2013;9(5):519–28. doi:10.2217/ahe.13.38
12. Czajkowski K, Broś‑Konopielko M, Teliga‑Czajkowska J. Urinary tract infection in women. Menopausal Rev (Prz Menopauzalny). 2021;20(1):40–47. doi:10.5114/pm.2021.105382.
13. Jia P, Zhu Y, Li X, Kudinha T, Yang Y, Zhang G, et al. High Prevalence of Extended-Spectrum Beta-Lactamases in Escherichia coli Strains Collected From Strictly Defined Community-Acquired Urinary Tract Infections in Adults in China: A Multicenter Prospective Clinical Microbiological and Molecular Study. Front Microbiol. 2021;12:663033. doi:10.3389/fmicb.2021.663033.
14. Mahdani W, Albela A, Hayati Z, Suhartono S. Prevalence of extended spectrum beta‑lactamase (ESBL) Escherichia coli recovered from ICU and non‑ICU at dr. Zainoel Abidin General Hospital. BIO Web of Conferences. 2024;94:02005. doi:10.1051/bioconf/20249402005.
15. Lewis SS, Knelson LP, Moehring RW, Chen LF, Sexton DJ, Anderson DJ. Comparison of non-intensive care unit (ICU) versus ICU rates of catheter-associated urinary tract infection in community hospitals. Infect Control Hosp Epidemiol. 2013;34(7):744-747. doi:10.1086/671000.
16. Siriphap A, Kitti T, Khuekankaew A, Boonlao C, Thephinlap C, Thepmalee C, et al. High prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates: A 5-year retrospective study at a Tertiary Hospital in Northern Thailand. Front Cell Infect Microbiol. 2022;12:955774. Published 2022 Aug 8. doi:10.3389/fcimb.2022.955774.
17. Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B. Prevalence of ESBL in Escherichia coliIsolates Among ICU Patients in a Tertiary Care Hospital. J Clin Diagn Res. 2016;10(9):DC19-DC22. doi:10.7860/JCDR/2016/21260.8544.
18. Elmawati EW, Pratiwi DIN, Muthmainah N, Biworo A. Antibiotic Susceptibility Pattern of Extended‑Spectrum Beta‑Lactamase‑Producing Klebsiella pneumoniae and Escherichia coli. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2021 Jul;27(3):282–288. doi:10.24293/ijcpml.v27i3.1634.